Join to View Full Profile
825 Eastlake Ave E"# G3-200"Seattle, WA 98109
Phone+1 206-288-6739
Fax+1 206-288-6473
Are you Dr. Shustov?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andrei Shustov, MD is an oncologist in Seattle, Washington. He is currently licensed to practice medicine in Washington. He is an Assistant Professor at University of Washington School of Medicine.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
Wellspan Health/York HospitalResidency, Internal Medicine, 2000 - 2003
Crimea State Medical UniversityClass of 1993
Certifications & Licensure
WA State Medical License 2003 - 2026
Publications & Presentations
PubMed
- 4 citationsGeographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses.Edward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, César Camilo Carías Alvarado, Juan Carlos Barrios Menéndez
Blood Advances. 2024-07-23 - Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.Noam E Kopmar, Megan Othus, Kim Quach, Allegra Rasmussen, Kelda Schonhoff
Transplantation and Cellular Therapy. 2024-07-01 - 5 citationsPhase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, Olga Sala-Torra, Philip A Stevenson
Leukemia & Lymphoma. 2023-05-01
Authored Content
- 'Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results ofAugust 2018
Press Mentions
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s MacroglobulinemiaAugust 26th, 2024- ALK-Negative Anaplastic Large Cell Lymphoma: Features and Outcomes of 235 Patients from the International T-cell ProjectJanuary 27th, 2021
- Duvelisib Response Rate Encouraging in Phase 2 PRIMO Trial of Patients with r/r PTCLDecember 7th, 2020
- Join now to see all
